NADI Diabetes Complications Conference & Grand Rounds: A Complete Archive and Guide to Diabetic Complications in Malaysia
Since 2002, the National Diabetes Institute (NADI) of Malaysia has organised one of the country’s most important continuing medical education (CME) programmes for healthcare professionals managing diabetes. The Diabetes Complications Conference & Grand Rounds — held annually or biannually alongside the Diabetes Asia Conference (DAC) series — has brought together endocrinologists, general practitioners, nephrologists, ophthalmologists, cardiologists, podiatrists, and diabetes educators to address the growing burden of diabetes complications in Malaysia.
This page serves as an archive of the conference series and a comprehensive resource on diabetic complications for both healthcare professionals and patients in Malaysia.
About the Conference Series
NADI is a non-profit, non-governmental organisation managed by a Board of Trustees comprising representatives from the Malaysian Endocrine and Metabolic Society (MEMS), Diabetes Malaysia (DM), and the Ministry of Health (MOH) Malaysia. Its patron is former Prime Minister YABhg. Tun Dr. Mahathir Mohamad.
The CPD (Continuing Professional Development) conference series was established in recognition of a pressing reality: the prevalence of diabetes mellitus, especially type 2, is on the increase, and this rise is most marked in developing countries, Malaysia included. There is an urgent need for strategies to prevent this epidemic, for early diagnosis of diabetes, and for ensuring optimal management of the disease, its complications, and associated diseases.
The Diabetes Complications Conference & Grand Rounds specifically focuses on the prevention and effective management of diabetic complications — particularly diabetic foot disease, cardiovascular disease, retinopathy, and nephropathy — with emphasis on recent advances and practical clinical applications.
Conference History: Key Editions
| Edition | Year | Theme / Focus | Format |
|---|---|---|---|
| CPD Series launch | 2002 | Inaugural NADI diabetes CPD programme | Annual |
| Diabetes Asia Conference (DAC) | 2008 onwards | Expanded to emphasise Asian diabetes presentation and management | Annual |
| 11th CPD — Diabetes Asia 2012 | 2012 | Diabetes management in Asian populations | Conference |
| 7th Diabetes Complications Conference | 2014 | Diabetic complications — foot, eye, kidney, heart | Grand Rounds |
| 8th Diabetes Complications Conference | May 2016 | Advances in complication prevention and management | Grand Rounds |
| Diabetes Asia 2017 Conference | 2017 | Asian-specific diabetes care advances | Conference |
| Diabetes Complications 2017 | 2017 | Multidisciplinary complications management | Grand Rounds |
| 10th Diabetes Complications Conference | 2018 | Held at The Waterfront Hotel | Grand Rounds |
| Diabetes Complications 2019 | 2019 | Practical management of diabetic complications | Grand Rounds |
| 12th Diabetes Complications Conference | 27–29 March 2020 | Prevention and effective management of diabetic complications | Grand Rounds, Hotel Istana KL |
| NADI Virtual Seminar: Diabetes & The Heart | 2022 | Cardiovascular complications in diabetes | Virtual |
| Diabetes Complications 2023 | 2023 | Latest advances in complication management | Grand Rounds |
| DAC 2025 | 2025 | International speakers, free paper presentations | Conference |
The 12th Diabetes Complications Conference & Grand Rounds, held in March 2020 at Hotel Istana, Kuala Lumpur, was approved for a maximum of 20 CPD points and targeted healthcare professionals responsible for managing people with diabetes across all disciplines.
Why Diabetic Complications Are Malaysia’s Most Urgent Health Challenge
The urgency behind NADI’s conference series is rooted in hard data. Diabetes prevalence in Malaysia reached 15.6% in 2023, continuing an upward trend from 11.2% in 2011 — meaning roughly 3.6 million Malaysian adults are living with the condition. What makes this particularly dangerous is how diabetes silently damages multiple organ systems simultaneously, often for years before symptoms appear.
Data from Malaysia’s National Diabetes Registry paints a clear picture of the complications burden currently facing the country’s healthcare system:
- Diabetic kidney disease (nephropathy): Among 80,360 T2D patients studied using the 2022 NDR clinical audit dataset, 56.7% were found to have diabetic kidney disease. The National Diabetes Registry 2023 separately reported that 12.7% of monitored patients had diagnosed nephropathy — a figure that underrepresents the true prevalence since many cases go undetected until advanced stages.
- Diabetic retinopathy: Diabetic retinopathy (10.4%) was the most common clinically diagnosed complication in the NDR audit dataset, making it the leading cause of preventable blindness among working-age Malaysians.
- Cardiovascular disease: Ischaemic heart disease affects 5.1% of Malaysian diabetes patients. Cardiovascular disease remains the leading cause of death among people with diabetes worldwide, and Malaysian patients are at particularly high cardiorenal risk — 99% of patients in a 2024 study of over 5,000 Malaysian diabetics were classified as high or very high cardiorenal risk.
- Diabetic foot disease and amputation: Diabetic foot ulcers affect approximately 1.2% of Malaysian diabetes patients registered with the NDR, though real-world hospital data suggests the true figure is significantly higher. Up to 30% of diabetics will develop a foot ulcer over their lifetime, and globally there is an average of one leg amputation every 20 seconds.
- Neuropathy: Peripheral neuropathy — nerve damage causing numbness, pain, and loss of sensation in the feet — is estimated to affect up to 50% of people with long-standing diabetes and is the primary driver of diabetic foot ulcers.
The Four Major Diabetic Complications: What Every Malaysian Should Know
1. Diabetic Nephropathy (Kidney Disease)
The kidneys contain millions of tiny blood vessels that filter waste from the blood. Chronically elevated blood glucose damages these vessels, progressively impairing kidney function. In its early stages, nephropathy produces no symptoms — it is only detectable through urine tests (checking for albumin) and blood tests (checking eGFR, a measure of filtration rate).
Left untreated, nephropathy progresses to chronic kidney disease (CKD) and eventually end-stage renal disease (ESRD) requiring dialysis. Malaysia has one of the highest rates of dialysis patients in the Asia-Pacific region, with diabetes being the leading cause of kidney failure. Increasing age, male sex, longer duration of diabetes, obesity, hypertension, and poor HbA1c control are all significant risk factors for developing diabetic kidney disease.
Detection: Annual urine albumin-to-creatinine ratio (UACR) test and eGFR blood test. Both should be done every year for all people with diabetes, regardless of symptoms.
Prevention: Tight blood glucose control, blood pressure management (target below 130/80 mmHg), ACE inhibitors or ARBs for patients with early protein leakage, and newer medications including SGLT2 inhibitors which have demonstrated proven kidney-protective effects independent of their glucose-lowering action.
2. Diabetic Retinopathy (Eye Disease)
Diabetes damages the tiny blood vessels supplying the retina at the back of the eye. In early non-proliferative retinopathy, small vessel leaks and blockages develop without visual symptoms. As the condition progresses to proliferative retinopathy, abnormal new blood vessels grow and can rupture, causing severe vision loss or blindness.
Diabetic retinopathy is the leading cause of new blindness among working-age adults in Malaysia. The tragedy is that it is largely preventable through early detection and treatment. Intensive diabetes management with the goal of achieving near-normoglycaemia has been shown in large prospective randomised studies to prevent and/or delay the onset and progression of diabetic retinopathy and reduce the need for future ocular surgical procedures.
Detection: Annual dilated fundus examination by an ophthalmologist or trained screener. All people with type 2 diabetes should have their first eye screening at the time of diagnosis, not years later.
Treatment: Laser photocoagulation for proliferative retinopathy, anti-VEGF injections for diabetic macular oedema, and vitreoretinal surgery for advanced cases. Early treatment is dramatically more effective than intervention at advanced stages.
3. Diabetic Cardiovascular Disease
People with diabetes have two to four times the cardiovascular risk of non-diabetics. Chronic hyperglycaemia accelerates atherosclerosis (arterial plaque buildup), damages blood vessel walls, and promotes inflammation — a triple threat to the heart and brain. The result is dramatically elevated risk of heart attack, stroke, heart failure, and peripheral arterial disease.
In Malaysia, managing cardiovascular risk in diabetes requires treating not just blood glucose but blood pressure and cholesterol simultaneously. Among over 5,000 Malaysian diabetes patients studied, the proportion who attained blood pressure below 130/80 mmHg was only 22.8% — far below what is needed for adequate cardiovascular protection.
Newer drug classes — particularly SGLT2 inhibitors (such as empagliflozin and dapagliflozin) and GLP-1 receptor agonists (such as semaglutide and liraglutide) — have demonstrated significant reductions in major cardiovascular events in clinical trials and are increasingly incorporated into Malaysian treatment guidelines for high-risk patients.
4. Diabetic Foot Disease
Diabetic foot complications arise from the combination of peripheral neuropathy (loss of sensation) and peripheral arterial disease (reduced blood flow). Loss of protective sensation means patients cannot feel minor injuries — a small blister from ill-fitting shoes, a cut from walking barefoot — which then become infected and fail to heal due to poor circulation. Without aggressive treatment, infection spreads to bone (osteomyelitis) and gangrene develops, leading to amputation.
Up to 50% of diabetic peripheral neuropathy may be asymptomatic — if not recognised and if preventive foot care is not implemented, people with diabetes are at risk for injuries as well as diabetic foot ulcers and amputations.
Prevention is everything with diabetic foot disease:
- Inspect your feet daily — look between toes for cuts, blisters, redness, or swelling
- Never walk barefoot, even indoors
- Wear well-fitting, protective footwear; avoid tight shoes or open-toed sandals
- Wash feet daily in lukewarm (not hot) water and dry thoroughly between toes
- Have a foot examination by your doctor at every diabetes clinic visit
- Seek immediate medical attention for any foot wound — do not attempt to treat at home
The Role of CME Conferences in Improving Diabetes Care in Malaysia
The NADI Diabetes Complications Conference & Grand Rounds plays a critical role in Malaysia’s diabetes care ecosystem by bridging the gap between emerging global evidence and frontline clinical practice.
General practitioners (GPs) manage the majority of diabetes patients in Malaysia, yet many have limited formal training in the nuanced management of diabetic complications — particularly newer pharmacological agents, multidisciplinary care pathways, and the practical application of rapidly evolving clinical guidelines. The Grand Rounds format — where complex real patient cases are presented and discussed by multidisciplinary panels — is particularly effective for translating academic evidence into practical clinical decision-making.
The scale of the unmet need is significant. Among high-risk patients with type 2 diabetes in Malaysia, treatment target attainment and use of guideline-directed medical therapy were suboptimal, with only 18% of patients achieving two or more of the key treatment targets simultaneously. Continuous professional education is a cornerstone of addressing this gap.
For healthcare professionals seeking CME events on diabetes in Malaysia, NADI continues to organise annual programmes including the Diabetes Asia Conference (DAC) and the Clinic Diabetes: Learning from KOLs (CDC) series. Information on upcoming events is available at nadidiabetes.com.
For Patients: When to Seek Specialist Review
If you have been diagnosed with type 2 diabetes, do not wait for symptoms before checking for complications. Most diabetic complications are silent in their early stages — detectable only through screening tests. The following screening schedule is based on MOH Malaysia guidelines:
- HbA1c: Every 3 months if not at target; every 6 months if well controlled
- Kidney function (UACR + eGFR): Annually
- Eye examination (dilated fundus): Annually
- Foot examination: At every clinic visit; comprehensive annual review
- Blood pressure: At every clinic visit
- Lipid profile: Annually or as directed by your doctor
- ECG: Annually for patients with cardiovascular risk factors
If any screening test detects abnormalities, prompt referral to the appropriate specialist — nephrologist, ophthalmologist, cardiologist, or vascular surgeon — can prevent progression to end-stage disease in the majority of cases.
References
- Ministry of Health Malaysia — National Diabetes Registry Report 2023. moh.gov.my
- Institute for Public Health — National Health and Morbidity Survey (NHMS) 2023. Ministry of Health Malaysia.
- Lim LL et al. (2024). Real-world evaluation of care for type 2 diabetes in Malaysia: TARGET-T2D study. PLOS One. doi:10.1371/journal.pone.0296298
- Wan Zuki WMH et al. (2024). Prevalence of diabetic kidney disease among T2D patients in Malaysia. Scientific Reports. nature.com
- American Diabetes Association (2024). Standards of Care in Diabetes — Retinopathy, Neuropathy, and Foot Care. Diabetes Care. diabetesjournals.org
- National Diabetes Institute (NADI) Malaysia — nadidiabetes.com
- eMedEvents — 12th Diabetes Complications Conference & Grand Rounds 2020. emedevents.com
This article is for general informational and educational purposes. Healthcare professionals should refer to current Malaysian CPG guidelines and attend accredited CME programmes for clinical decision-making guidance.